Clinical trial
A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin®…
NCT00209261 · Ferring Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00209261 |
|---|---|
| Title | A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) |
| Official title | A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate (120 μg and 240 μg) and 2 Different Daily Doses of Minirin® Tablet (0.2 mg and 2 x 0.2 mg) in Children and Adolescents With Primary Nocturnal Enuresis (PNE) |
| Acronym | PALAT |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Primary Nocturnal Enuresis |
| Intervention type | Drug |
| Interventions | MINIRIN Oral Lyophilisate, Minirin tablet |
| Enrollment | 221 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | May 19, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: